Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: Findings from the INFORCE study

Value in Health

Volumn 13, Issue 6, 2010, Pages 726-734

  Reckless, John ^a   Davies, Glenn ^b   Tunceli, Kaan ^b   Hu, X Henry ^b   Brudi, Philippe ^b  

^a UNIVERSITY OF BATH   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

coronary disease; cost effectiveness; drug therapy; ezetimibe; hydroxymethylglutaryl CoA reductase inhibitors (statins); hypercholesterolemia; prevention and control

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM;

EID: 77956353427     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00742.x     Document Type: Article

References (73)

1. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 113 : e85 151.
2. World Health Organization. Chapter 4: quantifying selected major risks to health. In: World Health Report 2002: Reducing Risks, Promoting Healthy Life. Available from: http://www.who.int/whr/2002/en. [Accessed August 25, 2009 S, Peto R, Scarborough P, et al. Chapter 1. Mortality. In : Coronary Heart Disease Statistics (16th ed.). London : BHF, 2008. 12 42. Available from: http://www.heartstats.org/temp/2008.Chaptersp1.pdf. [Accessed August 23, 2009 S, Peto V, Scarborough P, et al. Chapter 2. Morbidity. In : Coronary Heart Disease Statistics (16th ed.). London : BHF, 2008. 43 62. Available from: http://www.heartstats.org/temp/2008.Chaptersp2.pdf. [Accessed August 23, 2009 JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002 88 : 597 603.
3. Atella V, Brady A, Catapano AL, et al. Bridging science and health policy in cardiovascular disease: focus on lipid management: a report from a Session held during the 7th International symposium on multiple risk factors in cardiovascular diseases: prevention and intervention - health policy, in Venice, Italy, on 25 October, 2008. Atheroscler Suppl 2009 10 : 3 21.
4. Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002 106 : 3143 3421.
5. British Cardiac Society. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005 91 (Suppl. 5 v1 52.
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 14 (Suppl. 2 S1 113.
7. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 2006 17 : 631 636.
8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 366 : 1267 1278.
9. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 696.
10. Sever PS. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)? Am J Med 2005 118 (Suppl. 12A 3 9.
11. Collins R, Armitage J, Parish S, et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004 363 : 757 767.
12. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 : 2005 2016.
13. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 : 7 22.
14. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 : 1383 1389.
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 : 1495 1504.
16. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 291 : 1071 1080.
17. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 1435.
18. Catapano AL. Perspectives on low-density lipoprotein cholesterol goal achievement. Curr Med Res Opin 2009 25 : 431 447.
19. Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin 2008 24 : 1951 1963.
20. Assmann G, Schulte H, Cullen P, et al. Treatment of hyperlipidemia in primary practise in Germany: sub-group analyses from the 4E-registry with particular emphasis on men and women with diabetes mellitus. Exp Clin Endocrinol Diabetes 2007 115 : 85 91.
21. Rajagopalan S, Alemao E, Finch L, Yin D. Impact of new Joint British Societies' (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice. Curr Med Res Opin 2007 23 : 2027 2034.
22. Assmann G, Benecke H, Neiss A, et al. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006 13 : 776 783.
23. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005 21 : 1389 1399.
24. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 160 : 459 467.
25. UK Department of Health. Coronary heart disease: national service framework for coronary heart disease - modern standards and service models. 2000. Available from: http://www.dh.gov.uk/prod-consum-dh/groups/dh- digitalassets/@dh/@en/documents/digitalasset/dh-4057526.pdf. [Accessed August 27, 2009 P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf) 2006 64 : 292 298.
26. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000 321 : 1322 1325.
27. Mok HY, von Bergmann K, Grundy SM. Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res 1979 20 : 389 398.
28. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005 102 : 8132 8137.
29. Brudi P, Reckless JP, Henry DP, et al. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology 2009 113 : 89 97.
30. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract 2008 62 : 539 554.
31. Roeters van Lennep HW, Liem AH, Dunselman PH, et al. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr Med Res Opin 2008 24 : 685 694.
32. Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005 59 : 1377 1386.
33. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006 81 : 1579 1588.
34. Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005 102 : 327 332.
35. Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005 21 : 571 578.
36. Cook JR, Yin D, Alemao E, Drummond M. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia. Pharmacoeconomics 2004 22 (Suppl. 3 37 48.
37. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 101 : 207 213.
38. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997 80 : 106 107.
39. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991 121 (1 Pt 2 293 298.
40. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000 139 (2 Pt 1 272 281.
41. Office for National Statistics. Mortality Statistics: Deaths Registered in 2006; Review of the Registrar General on Deaths in England and Wales, 2006. Newport : Office of Public Sector Information (OPSI), Her Majesty's Stationery Office (HMSO), 2007. Available from: http://www.statistics.gov.uk/downloads/ theme-health/DR-2006/DR-06Mort-Stats.pdf. [Accessed August 27, 2009 JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000 19 : 3219 3236.
42. Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 1999 92 : 177 182.
43. Desgagné A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998 13 (5 Pt 1 487 497.
44. Hunink MG, Bult JR, de Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998 18 : 337 346.
45. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997 6 : 327 340.
46. Campbell M, Torgerson D. Confidence intervals for cost-effectiveness ratios: the use of "bootstrapping". J Health Serv Res Policy 1997 2 : 253 255.
47. Nixon RM, Wonderling D, Grieve RD. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared. Health Econ 2010 19 : 316 333.
48. Briggs A. Chapter 13. In : Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory with Practice. New York, NY : Oxford University Publishers, 2001.
49. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY : Chapman & Hall, 1993.
50. Olsson A, Casciano R, Stern L, Svangren P. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. Int J Cardiol 2004 96 : 51 7.
51. Mihaylova B, Briggs A, Armitage J, et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 2005 365 : 1779 1785.
52. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997 336 : 332 336.
53. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999 159 : 593 600.
54. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001 141 : 727 734.
55. Caro J, Klittich W, McGuire A, et al. The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997 315 : 1577 1582.
56. Hirsch M, O'Donnell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol 2005 104 : 251 256.
57. Buller N, Gillen D, Casciano R, et al. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom. Pharmacoeconomics 2003 21 (Suppl. 1 25 32.
58. Chau J, Cheung BM, McGhee SM, et al. Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. Hong Kong Med J 2001 7 : 360 368.
59. Kohli M, Attard C, Lam A, et al. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Pharmacoeconomics 2006 24 : 815 830.
60. Ara R, Pandor A, Tumur I, et al. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries. Clin Ther 2008 30 : 1508 1523.
61. Kotseva K, Stagmo M, De Bacquer D, et al. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008 197 : 710 717.
62. Ferrières J, Bataille V, Leclercq F, et al. Patterns of statin prescription in acute myocardial infarction: the French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI). Atherosclerosis 2009 204 : 491 496.
63. National Institute for Health and Clinical Excellence. Clinical Guideline on Lipid Modification Including Recommendations and Methods Used. London : Royal College of General Practitioners, 2008. Available from: http://www.nice.org.uk/nicemedia/pdf/CG67FullGuideline.pdf. [Accessed March 5, 2010 M, Drummond M, Willke R, et al. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005 8 : 10 23.
64. Jönsson B. Economics of drug treatment: for which patients is it cost effective to lower cholesterol? Lancet 2001 358 : 1251 1256.
65. Spencer FA, Goldberg RJ, Gore JM, et al. Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl. Am J Cardiol 2007 100 : 913 918.
66. Chenot F, Montant PF, Marcovitch O, et al. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest 2007 37 : 357 363.
67. IMProved Reduction of Outcomes: vytorin efficacy international trial - IMPROVE-IT. NCT #00202878. Available from: http://clinicaltrials.gov/ct2/show/ NCT00202878?term=IMPROVE+IT&rank=1. [Accessed March 25, 2010 MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003 326 : 1423 1427.
68. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010 55 : 198 211.
69. Wattanasuwan N, Khan IA, Gowda RM, et al. Effect of acute myocardial infarction on cholesterol ratios. Chest 2001 120 : 1196 1199.
70. National Institute for Health and Clinical Excellence. Guideline 67. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London : NICE, 2008. Available from: http://www.nice.org.uk/nicemedia/pdf/ CG67NICEguideline.pdf. [Accessed August 27, 2009 K, Puhan MA, Steurer J, Bachmann LM. Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 2007 153 : 722 731.
71. Diverse Populations Collaborative Group. Prediction of mortality from coronary heart disease among diverse populations: is there a common predictive function? Heart 2002 88 : 222 228.
72. Palmer S, Sculpher M, Philips Z, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service? Int J Cardiol 2005 100 : 229 240. Available from: http://www.nice.org.uk/Docref.asp?d=32030. [Accessed August 27, 2009 P, Gray A, Legood R, et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003 20 : 442 450.
73. National Health Service, England and Wales. Electronic Drug Tariff: Compiled. London : NHS, 2009. Available from: http://www.ppa.org.uk/edt/March- 2009/mindex.htm. [Accessed August 25, 2009 ].